Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Cattle vaccine could benefit human health

E. coli vaccine may reduce human cases by 85 per cent, say scientists

A new study suggests that vaccinating cattle against E. coli O157 could reduce the amount of human cases of infection by 85 per cent.

Scientists from the University of Glasgow led the research in collaboration with the University of Edinburgh and the Royal Veterinary College (RVC).

According to the RVC, current cattle vaccines against the bacterium are rarely used, but new findings suggest that the benefits to human health could be significant.

Researchers examined the level of risk of E. coli O157 transmission from cattle to humans, and the impact of vaccinating cattle.

Scientists at the RVC say the risk of E.coli O157 infection is particularly high when cattle are "super-shedding" - passing a very large amount of bacteria in their faeces for a limited time.

According to the research team, vaccinating cattle against the bacteria could reduce super-shedding, and therefore they predict that by using the vaccine, human cases of infection could be cut by nearly 85 per cent. 

"E. coli O157 is a serious gastrointestinal illness," says Dr Louise Matthews of the University of Glasgow's Institute of Biodiversity, Animal Health and Comparative Medicine.

"The economic impact is also serious – for instance studies in the US suggest that healthcare, lost productivity and food product recalls due to E. coli O157 can cost hundreds of millions of dollars each year."

One cattle vaccine in the US is not currently licensed as veterinary medicines must be proven to be beneficial to animal health. E. coli O157, however, does not harm cattle. In order to address this, the RVC says human and veterinary health practitioners must work together.

Senior author Professor Stuart Reid of the RVC adds: "This study is an excellent example the interface between veterinary and human medicine and of the concept of ‘One Health’ in action – controlling infections in animals can have a major impact on public health."

 
Related News
Concerns over resistant E. coli superbugs
Research into antibiotic resistant E. coli 

 

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.